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Myc oncogenetic deregulation is abundantly described in several solid human cancer and lymphomas. Particularly,
Burkitt's lymphoma belongs to the family of B Non Hodgkin aggressive lymphomas. Although it is morphologically
characterized, immunophenotypic and cytogenetic diagnosis remains complex. In 2008, the WHO has introduced a
new diagnostic class of aggressive B-cell lymphomas with features intermediate between BL and DLBCL. This
diagnostic class represents a temporary container of aggressive B-cell lymphomas, not completely belonging to the
BL and DLBCL categories. The importance of establishing a correct diagnosis would allow a better prognostic
classification and a better therapeutic approach. In this review, we summarize the main diagnostic approaches
necessary for appropriate diagnoses and we emphasize the importance of cytogenetic analysis of the oncogene
Myc in the histopathological diagnosis and the prognostic/predictive stratification. In this contest, Myc represents
the more involved gene in the development of these lymphomas. Therefore, we analyze the genetic aberrations
causing its over-expression and the concomitant deregulation of molecular pathways related to it. We also propose
a FISH approach useful in the diagnosis of these lymphomas.
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B-cell lymphoma unclassifiableIntroduction
Chromosomal translocations involving the immunoglobu-
lin genes are common in B-cell non-Hodgkin lymphomas
[1,2]. Some translocations are characterizing specific
lymphoma histotypes and are often considered as
cancer-initiating events [3]. For instance, t(8;14)(q24;
q32), that involves Myc and IgH genes, is generally
considered a hallmark of Burkitt Lymphoma (BL), but
this translocation is not the only cytogenetic alteration
observed in this type of lymphoma. BL is an aggressive
non-Hodgkin B-cell lymphoma (B-NLH) characterized
by the most rapidly growing cells [4]. It represents the
first human tumor associated to a specific viral infection* Correspondence: r.franco@istitutotumori.na.it
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reproduction in any medium, provided the orand one of the first with a chromosomal rearrangement
activating an oncogene [5,6]. Recent evidence suggests
that lipid pathway is altered in BL. Indeed neoplastic cells
are characterizated by the accumulation of lipid vacuoles
[7]. Conventionally three clinical variants of BL have been
described: endemic (eBL), sporadic (sBL) and HIV–related
[8]. Histologically BL shows a “starry sky” appearance,
due to death cells and scattered tingible-body-laden
macrophages present in monomorphic B-cell popula-
tion background and a high proliferation rate is always
demonstrated [4]. Although these morphological char-
acteristics are observed in the BL, in adults a reliable
diagnosis is very difficult to produce, since a subset of
lymphomas with morphological features similar to BL
are described [9]. Particularly differential diagnosis from
some cases of diffuse large B cell lymphoma (DLBCL)
and from B-cell lymphoma, unclassifiable, often results
difficult. Even with the use of current diagnostic criteria,
the distinction is not precise; in fact the agreementLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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diagnosis of this subset of aggressive B lymphomas is
only 53 percent [10,11]. The distinction between BL
and DLBCL is clinically important, because these
lymphomas are treated with different chemotherapeutic
protocols and differ in their outcome [12].
Adult BL shows a rapdly developing disease, so diagno-
sis and staging are urgent because aggressive high-dose
chemo-therapy should be started as soon as possible.
Aggressive prophylaxis must be started immediately
after diagnosis is confirmed [13]. However the inter-
pretation of response is difficult because there isn’t a
single protocol [14]. In addition recently Rituximab has




C-Myc is a transcription factor, playing a role in the
control of the cell cycle progression. C-Myc belongs to aFigure 1 MYC. A) Schematic representation of MYC gene and protein domtranscription factors family that includes MYCL (L-Myc)
and MYCN (N-Myc) and it is located on 8q24 chromo-
some [16].Myc gene is composed by three exons and Myc
mRNAs generate two isoforms of Myc polypeptides: the
first, the shorter one, starts an internal AUG, the second,
that is longer, initiates at a CUG [17]. The shorter one
plays an important role in the stress response [18,19]
(Figure 1). In addition, it is involved in the regulation of
many other biological activities, such as differentiation,
apoptosis, angiogenesis, cell adhesion and motility, tel-
omerase activity and cell metabolism [20]. Myc is consid-
ered the human oncogene more frequently deregulated in
many types of cancer with subsequent, uncontrolled cell
proliferation, genomic instability, apoptosis, escape of im-
mune surveillance and cell immortalization [21,22].
Myc protein contains a basic region helix-loop-helix-
leucine zipper and modulates the expression of target
genes by binding to specific DNA sequences (E-Box).
Myc performs its function by dimerization with MAX, a
leucine-zipper transcription factors family. Recently, itains; B) MYC alteration in human cancer.
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(Germinal Center) is lower compared to naive and mem-
ory cells. Probably, this low expression could protect
against Myc-induced genomic instability in the GC [23].
Myc alteration in human cancer
Myc oncogenetic deregulation could be induced by
point mutations, gene amplification, translocation, epi-
genetic reprogramming, enhanced translation and
increased protein stability [21]. The effects are C-Myc
protein overexpression, demonstrated in 80% of breast
cancers, 70% of colon cancers, 90% of gynecological
cancers, 50% of hepatocellular carcinomas, 30% of lung
cancer and a variety of hematological tumors [24]. Aber-
rant Myc expression has also been identified in Prostatic
Cancer where it has been proposed as a potential prognos-
tic factor [25,26] (Figure 1B). Generally Myc gene amplifi-
cation has been described as the most frequent molecular
alteration in most of solid tumours [21]. In addiction
Single-nucleotide Polymorphisms (SNPs) within 8q24
chromosomal region have been found to be associated
with colorectal, breast, bladder, ovarian and prostate
cancers [26,27]. Furthermore, point mutations are re-
vealed in Myc N-terminal domain (residues 44-65), in
particular, the most frequently mutated residue is Thr-58.
The phosphorylation of this residue has been shown to
control c-Myc degradation and mutations, abolishing
Thr-58, lead to an increased c-Myc half life in BL
[28,29]. The translocation t(8;14) has been described as
the most frequent aberration involving Myc gene in BL
with the immunoglobulin heavy chain (IgH) gene as
partner. Less common aberration involves light chain
immunoglobulin genes (Igλ or Igκ) in the translocations
t(2;8) and t(8;22) [30]. The activation of the Myc gene at
8q24 is considered the main pathogenetic feature of BL,
but the contribution of other genetic mutations to the
disease is an important developing point [30]. In addition
Myc translocation is not only specifically observed in BL
but it can occur in other hematological malignancies. In-
deed Myc rearrangement is observed in 5-10% of diffuse
large B-cell lymphomas and up to 50% of high-grade B-
cell lymphomas other than Burkitt lymphomas [31]. In
these tumours, Myc translocations can also involve non-
IG partners [24].
Molecular pathways associated to MYC overexpression in
Burkitt lymphoma
Myc translocation in BL is considered as a lymphoma
initiating event, in other lymphomas it may also occur as
a secondary event during disease progression [3]. Well
documented oncogenetic alterations are associated to
other intracellular pathways.
Recently C. Love et al. have highlighted a series of
gene mutations in BL. For example, ID3 (inhibitor ofDNA binding protein) gene mutations produce a two-
fold higher gene expression in BL cells when compared
to DLBCL [32]. ID3 mutation is associated to increased
G to S phase cell cycle progression correlated to higher
expression of cell cycle pathway genes, such as E2F1,
CDK7, MCM10 and with an higher expression of known
Myc target genes. This phenomenon, through ID3 mi-
metics, could represent the possibility of a potential thera-
peutic approach in BL [32].
Using animal models, many studies have shown that
the translocation involving Myc could be mediated by
citidinedeaminase (AICDA) and that it is not activated
by the recombinase (RAG1/2). This suggests the presence
of somatic hypermutation or class switch recombination,
that may be detected in normal tissue [33,34].
Several papers described an overexpression of NF-kB
(Nuclear Factor kappa-light-chain-enhancer of activated
B cells) both in DLBCL and HL and its lower expression
in BL. Klapproth et al. suggest in a study realized on mice
and human that in c-Myc transformated lymphoma cells,
NF-kB-pathway is deregulated. Therefore they concluded
that c-MYC overexpression sensitizes cells to NF-κB–in-
duced apoptosis, and the absence of NF-κB signaling is
an assumption for MYC-mediated tumorigenesis [35].
Another study tried to explain the possible role of
IP3K (Inositol 1,4,5-Trisphosphate 3-kinase) and Myc in
primary events of lymphomagenesis, using mouse
models of BL. The results show a significant activation
of IP3K pathway, especially in cells where the signal of
NF-kB is off [36]. Recently, IP3K overexpression has
been found in human BL, suggesting a functional role in
BL pathogenesis [35]. The involvement of NF-kB and
IP3K pathways might have implication for the development
of therapies against MYC-positive tumours. Recent studies
highlight c-Myc influence on the Retinoblastoma (Rb) path-
ways. Rb gene family is composed by three (Rb, pRb2/p130
and p107) cell cycle regulator protein members. Cinti et al.
showed that several genetic alterations disrupt the nuclear
localization of the retinoblastoma-related gene RB2/p130
in human tumor cell lines and primary tumors [37]. In
particular, mutation of RB2/p130 caused the upregulation
of cyclins E1 and A2, involved in cell cycle progression
from G1 to S-phase, and the inactivation of the transcrip-
tion factor E2F4 (typically increasing during the S phase)
[38]. This alteration is more frequent in endemic BL and
lesser in sporadic BL. However, RB2/p130 mutation has
not been included into molecular signatures that distin-
guish BL and DLBCL, suggesting that RB2/p130 deregula-
tion was common in all B–non-Hodgkin lymphomas
(NHLs), and not exclusive for BL pathogenesis [39].
The INK4/ARF locus encodes two tumour suppressor
genes, p16 and p14 that distinctively regulate Rb and p53
pathways. Human and murine studies have showed that
the simultaneous c-Myc iperactivation and INK4/ARF
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of BL, conferring a further growth advantage and apop-
tosis protection to the cells [40,41]. Moreover, c-Myc, p14
and p16 are degraded with proteasome-dependent mech-
anism, and a less ubiquitination is demonstrated in BL.
These evidences suggest that proteasome inhibitors may
be further considered in the treatment of BL [42]. Re-
cent studies have highlighted that miRNAs (small non
coding RNA) may have a role in malignant transform-
ation in several solid tumors, but little is known about
their expression and deregulation in malignant lymph-
omas [43]. In particular, hsa-miR-155 was found to be
highly expressed in 90% of Hodgkin's lymphomas and
in diffuse large B-cell lymphomas. Moreover recent
studies have underlined its role in B-cell differentiation.
Furthermore, the miR-17-92 cluster was described as a
transcriptional target of c-Myc and it was over-expressed
during lymphomagenesis [44]. Other studies have assessed
that hsa-miR-127 up-regulation in EBV positive BL
confirming different pathogenetic mechanisms between
EBV-positive and EBV-negative BL [45]. We have sche-
matized in Figure 2 all the previously discussed path-
ways correlated to Myc gene aberration.
Detection of MYC gene/protein alteration
Several studies have demonstrated distinctive complex
karyotypes (CK) in BL and DLBCL. Havelange et al.
have identified recurrent alterations associated withFigure 2 Schematic representation of MYC translocation and moleculMyc rearrangements in 84 aggressive B-cell lymph-
omas by multicolor fluorescence in situ hybridization
(M-FISH). They concluded that BL karyotypes were
less complex and aneuploid than other lymphomas
with Myc-rearrangement. This condition suggests that
BL with CK are indeed different from other aggressive
MYC-rearranged lymphomas, usually showing wider
genetic complexity [46]. Several Comparative genomic
hybridization (CGH) studies highlight genomic imbal-
ances in BL. Garcìa et al. found chromosomes 12q, Xq,
22q, 20q, 9q gains, and chromosomes 13q and 4q
losses. Moreover they found high level of amplification
in the regions 1q23-31, 6p12-p25, 8p22-23 [47]. Anyway
previous studies have determined that BL has a simple
karyotype < or=2 additional abnormalities and it is associ-
ated to better overall survival respect to other B aggressive
lymphomas, this condiction is generally observed in BLs
[48]. Gains or amplifications of chromosomes 1q and 7q
(respectively 20% and 10% of BL) have been associated
with worse clinic outcome and also all 13q chromosomal
abnormalities have been related to an aggressive behaviour
[47,49,50]. Furthermore, recently, a comparative analysis
between whole-genome oligonucleotide array CGH ana-
lysis and FISH in a Burkitt's lymphoma-derived cell lines,
showed three minimal critical regions (MCR) localized on
Chr 1q harboring several genes such as BCA2, PIAS3 and
MDM4 and AKT3. These regions appear critically in-
volved in BL prognosis [51].ar pathways involved in lymphomagenesis.
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cytogenetic signature of BL as shown by its routinely use
in several diagnostic algorithms. This investigation is
fundamental in differential diagnosis with other lymph-
omas morphologically similar to BL but with atypical
immunophenotype or genetic signatures.
Hummel et al. proposed a “BL similarity index”, based
on the analysis of 58 genes, classifying aggressive NHL
into molecular BL (mBL), intermediate cases, and non
molecular Burkitt. They analysed 220 mature aggressive
B-cell lymphomas, and identified a consistent gene
panel characteristic of molecular BL. These genes also
included several target genes of the nuclear factor-κB
pathway (i.e., BCL2A1, FLIP, CD44, NFKBIA, BCL3, and
STAT3) that normally distinguished activated B-cell-like
(ABC) or germinal-center B-cell-like lymphomas (GC)
[52,53]. Through this index yet not all cases with mor-
phologic or immunophenotypical features of Burkitt’s
lymphoma were classified as mBL. Molecular signature
was strongly supported from the genetic analysis that
defines three groups: i) the myc-simple group character-
ized by IG-Myc fusion and a low number of chromosomal
imbalances (complexity score < 6, MYC translocation
could be the primary oncogenic event) largely overlapped
with the molecular BL and associated with a favourable
clinical outcome; ii) Myc-complex status (complexityFigure 3 Above, FISH assay shows the MYC locus rearrangement wit
Rearrangement Probe Kit). A. MYC rearrangement-positive tumor cells,
B. Absence of MYC translocation, showing fusion signal patterns; Below, F
IGH/MYC/CEP 8 Tri-Color DF FISH Probe Kit): C. The reciprocal t(8;14) in tu
green fusions, and two aqua centromeric signals; D. Absence of reciproca
signals pattern.score > 6, Myc translocation could be the second onco-
genic event) associated with a poor outcome, independ-
ently of age and clinical stage corresponding to the
intermediate group; iii) Myc negative group including non
molecular Burkitt cases [53].
On the basis of current literature, Bellan et al. sug-
gested a practical approach for BL diagnosis. To distin-
guish among BL, DLBCL and the provisional category
of “unclassifiable B-cell lymphoma”, with intermediate
features between DLBCL and BL (BCLU), they used
cytogenetic, molecular and immunohistochemical tech-
niques, selecting a large panel of antibodies. In particular,
FISH analysis was performed to detect the translocations
involving Myc, BCL2 and BCL6 through commercially
available probes [54].
Myc translocation could be easily detected through the
use of commercial probes by breaking apart or by dual
fusion strategy used for FISH analyses. The first strategy
allows, in a single approach, to assess the integrity of the
Myc gene, but it does not provide information about the
translocation partner. Known translocation partners of
Myc gene could be detected using the second strategy
(Figure 3). Several commercial probes are available, but
they detect separately the different Myc partners. In fact
some Break Apart probes, investigating the presence of
Myc rearrangements in the locus corresponding to Igλh a break-apart probe (Vysis LSI MYC Dual Color Break Apart
showing one yellow fusion signal, one orange and one green signals;
ISH assay shows the IGH/MYC/CEP8 Tri-Color Dual Fusion probe (Vysis
mor cells showed a pattern of one orange, one green, two orange/
l translocation showed the two aqua, two orange, and two green
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dual fusion Myc probe allows the translocation t (8:14)
assessment. There are no commercial probes to investi-
gate the non-IG Myc partners. The Myc break apart probe
combined with the previously described probes are neces-
sary to detect this subset of translocations.
Naresh et al. proposed in the diagnostic approach of
BL an immunohistochemistry and FISH scoring system,
based on three phases. Particularly, the first phase is
based on the scoring of both the morphological features
and a small immunohistochemistry panel detections, in-
cluding BCL2 and CD10 antibodies. If the cumulative
score is ≥ 5, the diagnosis of BL can be proposed; if the
score is < 3 the diagnosis is not BL. The unresolved
cases with intermediate score should be further scored
through a larger panel of immunohistochemistry, such
as ki67 (score 0-1-2), CD38 (score 0-1) and CD44 (score
0-1). Only if cumulative scores is ≥8, diagnosis of BL is
definitively proposed. Finally, If this phase is uncertain,
FISH analysis, including Myc\IG translocation and
rearrangements of BCL2 and BCL6 should be crucial. If
cumulative scores is ≥8: diagnosis of BL; if the score is
between 6 and 7: BL not excluded. Through this approach
is possible enable to give lead to a precise diagnosis of BL
in more than 90% cases [55].
Instead, Salaverria et al. propose a genetic model of
pathogenesis of high-grade B cell lymphomas “gray zone”,
related to genetic aberration and age. The gray zone repre-
sents hybrid zone between classical BL and classical
DLBCL, and contain “secondary Burkitt-transformed
lymphomas” and many indeterminate lymphomas. Cyto-
genetically Sporadic BLs in children and adults are similar.
Both groups are characterized by the same low genomic
complexity including the same genetic aberrations. A cor-
rect subclassification of mature aggressive B-cell lymph-
omas in adults directly influence the therapeutic strategy.
This genetic model shows that real adult BLs are very rare
and that the BL with more genetic alteration is extremely
difficult to find. In this contest, the distinctive feature of
BL is represented by its low genomic complexity [56].
Myc translocation has not only diagnostic value but
it is also a powerful prognostic indicator in several
lymphomas.
Myc translocation is associated to poor prognosis in
other B aggressive lymphomas. Indeed LI S. et al. showed
several lymphoma cases with a germinal center B-cell
immunophenotype carryingMyc and BCL2 rearrangements
and clinically aggressive behaviour, independently of their
morphological appearance [57]. Pei Lin et al. assert that the
only Myc aberration, in unclassifiable B-cell lymphoma,
identifies patient subsets, requiring more aggressive therapy
than R-CHOP [58].
However, Myc can be regulated by other mechanisms
inducing its increased protein expression and itshyperactivation [59,60]. FISH is unable to detect
genetic deregulation that affects gene expression on
the transcriptional and translational levels unlike im-
munohistochemical analysis [61]. For a long time the
Myc evaluation by immunohistochemestry has been
hampered by a lack of anti-MYC antibodies that are
suitable to detect the increased protein expression.
However, recently a new commercial, Myc antibody
(clone Y69; Epitomics, Burlingame, CA) seems to be
useful in the diction of myc overexpression, independ-
ently from molecular mechanism. This monoclonal
antibody targets the Myc protein-N terminus. This
Myc antibody shows a typical nuclear staining and it
has been proposed a significant diagnostic cut-off in
BL for the immunoscoring when higher than 40%. Several
recent studies proposed to introduce this antibody in a
novel diagnostic alghorithm.
Green et al. analyse a group of DLBCL both trough
immunohistochemistry for Myc, BCL2, CD10, BCL6,
and MUM1/interferon regulatory factor 4, and FISH for
Myc and BCL2. They concluded that FISH analysis
identified Double-Hit Lymphoma (DHL) in 6% of
patients, while immunohistochemical MYC and BCL2
analyses identified a double-hit group that comprised
29% of patients. These cases were significantly associated
with shorter OS (P < .001), and shorter progression-free
survival (PFS; P < .001), concluding that the only MYC
and Bcl2 immunohistochemestry defined a large subset
of DLBCLs strongly associated with poor outcome in
patients treated with R-CHOP [62].
Finally, Horn et al. proposed to introduce a novel diag-
nostic approach using Myc antibody. They suggest a com-
bined immunohistochemical and FISH score to predict
outcome in DLBCL patients (score 0, when BCL2 <70%
and MYC <40%, score 1 MYC and Bcl2 expression near to
cut off and score 3, when Bcl2 and MYC expression is
more than cut-off) [63].
The routinely diagnostic application of Myc antibody
is not yet applied. Recent studies show Myc antibody
use in DLBCL where the percentage of Myc translocation
is very low [64]. In the future Myc antibody could be used
for the other B aggressive lymphomas, BL and BCLU, to




Detection of the Myc translocation is currently performed
by conventional cytogenetics, Southern blot, and polymer-
ase chain reaction–based methods. Nevertheless, all these
methods can fail to detect IG-Myc fusions [65]. The most
reliable method is cytogenetic analysis by fluorescence in
situ hybridization (FISH). Nowadays the molecular genet-
ics is fully integrated into the routine diagnostic of
Figure 4 The cytogenetics diagnostic algorithm. MYC rearrangement is recommended on lymphoma cases with increased Ki67 expression
(> 90%). Molecular Burkitt Lymphoma (BL) is defined only by the presence of the MYC-IG rearrangement, an early and frequent event; Diffuse
Large B-cell Lymphoma (DLBCL) is cytogenetically set by the absence of MYC aberration; Intermediate BL/DLBCL are defined by unstable
phenotype, generally MYC rearrangement is a second event and it doesn’t involve IG locus.
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but this analysis has not been introduced into routine
diagnostic laboratories because it is labour-intensive
and it has a high rate of failure [29]. Thus in the fu-
ture, the development of a FISH assay for simultan-
eous detection of all known Burkitt abnormalities will
be necessary.
We summarized a cytogenetic diagnostic “flowchart”
for a better and safer histopathologic diagnosis of
Burkitt (Figure 4). We recommend a first FISH ap-
proach using Myc Break Apart probe on lymphoma
cases with increased (>90%) Ki67, to identify all positive
samples for Myc translocations. BCL2 and BCL6 trans-
locations using Break Apart probes will be performed
on all negative samples. Finally on the positive speci-
mens should evaluate also the presence of IG-Myc
translocation through the use of a Dual colour dual
fusion Myc-IGH probe and IGK and IGL Break Apart
probes. Then, BCL2 and BCL6 status should be investi-
gated. In our opinion, this is the best approach to avoid
misdiagnosis of molecular BL but it is useful only if it is
integrated with morphologic and immunophenotypic
evaluation. The diagnosis of BL and other aggressive
B cell Lymphomas, with or without Myc breakpoints,represents an important start-point for future clinical
trials to establish different therapeutical strategies for
these lymphomas. Although the FISH-based algorithmic
approach results an important tool for BL diagnosis, it is
not easily accessible in most of the pathology laboratories
because it is an expensive method and so it remains a
speculative analysis.
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